Citi keeps this biotech stock a top pick after trial clears key efficacy milestone
Tweet Send to a Friend
Citi Research reiterated its "buy," Top Pick rating and $1,203 price target on this biopharmaceutical company after the Belgian biotech's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
